Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04570956). This is a study registration, not published results. Lead sponsor: Mayo Clinic. Recruitment status: TERMINATED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 65 participants (ACTUAL). Conditions: Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma. Interventions: DRUG: Tamoxifen; DRUG: Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day; DRUG: Placebo; OTHER: Questionnaire Administration. Primary outcome measures: Change in Median Lobular Ki67 From Pre-Tamoxifen Breast Biopsy to On-Tamoxifen Biopsy With 4 Weeks of Intervention , Pre-biopsy to post-biopsy following 4 weeks of intervention. Brief summary: The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).